Skip to main content

Market Overview

JP Morgan Initiates Bioline RX With Market Outperform


JP Morgan initiated coverage on Bioline RX Ltd (NASDAQ: BLRX) with a Market Outperform rating.

The target price for Bioline RX is set to $5.

Bioline RX shares have dropped 4.17 percent over the past 52 weeks, while the S&P 500 index has gained 7.51 percent in the same period.

Bioline RX shares gained 4.34 percent to $2.16 in pre-market trading.

Latest Ratings for BLRX

Feb 2021HC Wainwright & Co.MaintainsBuy
Dec 2020HC Wainwright & Co.MaintainsBuy
Aug 2017OppenheimerInitiates Coverage OnOutperform

View More Analyst Ratings for BLRX
View the Latest Analyst Ratings


Related Articles (BLRX)

View Comments and Join the Discussion!

Posted-In: JP MorganInitiation Analyst Ratings

Latest Ratings

CMGCredit SuisseMaintains1,875.0
PBRJP MorganUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at